8-KLeadership ChangesCorporate ChangesExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Executive Changes (Oct 17, 2008)

Filed October 17, 2008For Securities:ABT

Summary

Abbott Laboratories (ABT) filed an 8-K on October 17, 2008, reporting key corporate governance changes. The most significant event for investors is the immediate appointment of Dr. Robert J. Alpern, Dean of the Yale School of Medicine, to the Board of Directors as of October 10, 2008. This expansion of the board may signal a strategic focus on medical expertise or research and development, which could be relevant for assessing future growth and innovation within the company. Additionally, the company amended its bylaws to increase the size of its Board of Directors from thirteen to fourteen members, also effective October 10, 2008. This increase in board size, coupled with the addition of a highly credentialed medical professional, suggests potential adjustments to Abbott's governance structure and oversight. Investors should monitor how these changes might influence strategic decisions and corporate direction.

Key Highlights

  • 1Dr. Robert J. Alpern, Dean of the Yale School of Medicine, appointed to the Board of Directors effective October 10, 2008.
  • 2Abbott Laboratories amended its bylaws to increase the size of its Board of Directors.
  • 3The Board of Directors will now consist of fourteen members, up from thirteen.
  • 4The amendment to the bylaws and the director appointment are effective as of October 10, 2008.
  • 5The filing includes an amendment to the company's bylaws as an exhibit.
  • 6Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer, signed the report.
  • 7The report was filed on October 17, 2008, relating to events on October 10, 2008.

Frequently Asked Questions

The filing indicates that the Board of Directors was expanded from thirteen to fourteen members to accommodate the appointment of Dr. Robert J. Alpern. The specific reasons for the expansion and the strategic implications are not detailed in this 8-K, but it often signifies a desire for broader expertise or to support increased oversight and governance.

Dr. Robert J. Alpern is the Dean of the Yale School of Medicine. His appointment to the Board of Directors brings significant medical and academic expertise, suggesting a potential emphasis on the company's research, development, or medical strategy.

Both the amendment to the bylaws increasing the board size and the appointment of Dr. Robert J. Alpern to the Board of Directors are effective as of October 10, 2008.

This report details two main governance changes: the addition of a new director, Dr. Robert J. Alpern, and an increase in the total number of directors from thirteen to fourteen through an amendment to the company's bylaws.